4′‐modified nucleoside analogs: Potent inhibitors active against entecavir‐resistant hepatitis B virus

Authors:

Abstract
Certain nucleoside/nucleotide reverse transcriptase (RT) inhibitors (NRTIs) are effective against human immunodeficiency virus type 1 (HIV‐1) and hepatitis B virus (HBV). However, both viruses often acquire NRTI resistance, making it crucial to develop more‐potent agents that offer profound viral suppression. Here, we report that 4′‐C‐cyano‐2‐amino‐2′‐deoxyadenosine (CAdA) is a novel, highly potent inhibitor of both HBV (half maximal inhibitory concentration [IC50] = 0.4 nM) and HIV‐1 (IC50 = 0.4 nM). In contrast, the approved anti‐HBV NRTI, entecavir (ETV), potently inhibits HBV (IC50 = 0.7 nM), but is much less active against HIV‐1 (IC50 = 1,000 nM). Similarly, the highly potent HIV‐1 inhibitor, 4′‐ethynyl‐2‐fluoro‐2′‐deoxyadenosine (EFdA; IC50 = 0.3 nM) is less active against HBV (IC50 = 160 nM). Southern analysis using Huh‐7 cells transfected with HBV‐containing plasmids demonstrated that CAdA was potent against both wild‐type (IC50 = 7.2 nM) and ETV‐resistant HBV (IC50 = 69.6 nM for ), whereas ETV failed to reduce DNA even at 1 μM. Once‐daily peroral administration of CAdA reduced viremia (P = 0.0005) in human‐liver‐chimeric/ –infected mice, whereas ETV completely failed to reduce viremia. None of the mice had significant drug‐related body‐weight or serum human‐albumin concentration changes. Molecular modeling suggests that a shallower HBV‐RT hydrophobic pocket at the polymerase active site can better accommodate the slightly shorter 4′‐cyano of CAdA‐triphosphate (TP), but not the longer 4′‐ethynyl of EFdA‐TP. In contrast, the deeper HIV‐1‐RT pocket can efficiently accommodate the 4′‐substitutions of both NRTIs. The ETV‐TP's cyclopentyl ring can bind more efficiently at the shallow HBV‐RT binding pocket. Conclusion: These data provide insights on the structural and functional associations of HBV‐ and HIV‐1‐RTs and show that CAdA may offer new therapeutic options for HBV patients. (Hepatology 2015;62:1024‐1036)
Funding Information
  • Intramural Research Program of Center for Cancer Research, National Cancer Institute, National Institutes of Health
  • Health and Labor Sciences Research Grant (Practical Research on Hepatitis [Research on the innovative development and the practical application of new drugs for hepatitis B
  • International Research Center Aiming at the Control of AIDS, Kumamoto University (R01AI112417 and R01AI076119)

This publication has 37 references indexed in Scilit: